Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Dadachova, Mahesh Patel, S. Toussi, C. Apostolidis, A. Morgenstern, M. Brechbiel, M. Gorny, S. Zolla-Pazner, A. Casadevall, H. Goldstein (2006)
Targeted Killing of Virally Infected Cells by Radiolabeled Antibodies to Viral ProteinsPLoS Medicine, 3
B. Smart (2011)
Stem-Cell Gene Therapy for the Wiskott-Aldrich SyndromePediatrics, 128
Holland Hk, Rein Saral, Rossi Jj, A. Donnenberg, W. Burns, W. Beschorner, Homayoon Farzadegan, Richard Jones, Quinnan Gv, G. Vogelsang (1989)
Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection. Studies in a patient with non-Hodgkin lymphoma.Annals of internal medicine, 111 12
Quan-en Yang (2004)
Human immunodeficiency virus reservoir might be actively eradicated as residual malignant cells by cytotoxic chemotherapy.Medical hypotheses, 62 3
C. Smith, S. Lilly, G. Miralles (1998)
Treatment of HIV infection with cytoreductive agents.AIDS research and human retroviruses, 14 15
Bindong Liu, Xianghui Yu, K. Luo, Yunkai Yu, Xiao-Fang Yu (2004)
Influence of Primate Lentiviral Vif and Proteasome Inhibitors on Human Immunodeficiency Virus Type 1 Virion Packaging of APOBEC3GJournal of Virology, 78
J. Borvak, C. Chou, G. Dyke, B. Rosenwirth, E. Vitetta, O. Ramilo (1996)
The use of cyclosporine, FK506, and SDZ NIM811 to prevent CD25- quiescent peripheral blood mononuclear cells from producing human immunodeficiency virus.The Journal of infectious diseases, 174 4
C. Simard, P. Jolicoeur (1991)
The effect of anti-neoplastic drugs on murine acquired immunodeficiency syndrome.Science, 251 4991
Description of how anti-PD-1 antibody might be a potentially useful target in cure strategies for HIV
J. Bartlett, G. Miralles, A. Sevin, Martha Silberman, S. Pruitt, J. Ottinger, Victoria Gryszowska, S. Fiscus, R. Bucy (2002)
Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons.AIDS research and human retroviruses, 18 8
G. Hütter, D. Nowak, M. Mossner, S. Ganepola, A. Müssig, Kristina Allers, T. Schneider, J. Hofmann, C. Kücherer, O. Blau, I. Blau, W. Hofmann, E. Thiel (2009)
Long-Term Control of HIV by CCR 5 Delta 32 / Delta 32 Stem-Cell Transplantation
E. Berger (2011)
Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirsCurrent Opinion in HIV and AIDS, 6
T. Spitzer, R. Ambinder, Jeannette Lee, L. Kaplan, W. Wachsman, D. Straus, D. Aboulafia, D. Scadden (2008)
Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 14 1
R. Davey, C. Boenning, B. Herpin, D. Batts, J. Metcalf, L. Wathen, S. Cox, M. Polis, J. Kovacs, J. Falloon (1994)
Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus.The Journal of infectious diseases, 170 5
M. Michieli, M. Mazzucato, U. Tirelli, P. Paoli (2011)
Stem Cell Transplantation for Lymphoma Patients with HIV InfectionCell Transplantation, 20
E. Kang, U. Choi, N. Theobald, G. Linton, D. Priel, D. Kuhns, H. Malech (2010)
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.Blood, 115 4
A. Krishnan, J. Palmer, J. Zaia, N. Tsai, J. Alvarnas, S. Forman (2008)
HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL).Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 16 9
Clay Smith, S. Lilly, G. Miralles (1998)
Minireview: Treatment of HIV Infection with Cytoreductive AgentsAIDS Research and Human Retroviruses, 14
S. Alley, N. Okeley, P. Senter (2010)
Antibody-drug conjugates: targeted drug delivery for cancer.Current opinion in chemical biology, 14 4
L. Contu, G. LaNasa, M. Arras, A. Pizzati, A. Vacca, Carlo Carcassi, Antonio Ledda, R. Boero, S. Orrù, A. Pintus (1993)
Allogeneic bone marrow transplantation combined with multiple anti-HIV-1 treatment in a case of AIDS.Bone marrow transplantation, 12 6
B. Zweiman (2019)
Neutrophils.Clinical allergy and immunology, 16
Quan-en Yang, Kun Li, J. Mikovits (2002)
Eradication of human immunodeficiency virus type 1-infected cells by a combination of antimetabolic cytotoxic chemotherapy and antiviral chemotherapy in vitro: a pilot study.The Journal of infectious diseases, 186 5
Franco Lori, Andrei Malykh, Andrea Foli, Renato Maserati, Anna Antoni, Lorenzo Minoli, Daniela Padrini, Annamaria Antoni, Enrico Barchi, Heiko Jessen, M. Wainberg, Robert Gallo, J. Lisziewicz (1997)
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance.AIDS research and human retroviruses, 13 16
Clear demonstration of the clinical utility of using ZNF nuclease directed to CD19 as a means of controlling cancer growth in patients with refractory CLL
N. Archin, A. Liberty, A. Kashuba, S. Choudhary, J. Kuruc, A. Crooks, D. Parker, E. Anderson, M. Kearney, M. Strain, D. Richman, M. Hudgens, R. Bosch, J. Coffin, J. Eron, D. Hazuda, D. Margolis (2012)
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapyNature, 487
H. Lane, K. Zunich, W. Wilson, F. Cefali, M. Easter, J. Kovacs, H. Masur, S. Leitman, H. Klein, R. Steis (1990)
Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection.Annals of internal medicine, 113 7
S. Topalian, F. Hodi, J. Brahmer, S. Gettinger, David Smith, David McDermott, J. Powderly, Richard Carvajal, J. Sosman, M. Atkins, P. Leming, D. Spigel, S. Antonia, L. Horn, Charles Drake, D. Pardoll, Lieping Chen, W. Sharfman, Robert Anders, J. Taube, T. McMiller, Haiying Xu, A. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. Kollia, A. Gupta, J. Wigginton, M. Sznol (2012)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.The New England journal of medicine, 366 26
R. Piekarz, R. Frye, H. Prince, M. Kirschbaum, J. Zain, S. Allen, E. Jaffe, A. Ling, M. Turner, C. Peer, W. Figg, S. Steinberg, Sonali Smith, D. Joske, I. Lewis, L. Hutchins, M. Craig, A. Fojo, J. Wright, S. Bates (2011)
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.Blood, 117 22
R. Little, S. Pittaluga, N. Grant, S. Steinberg, M. Kavlick, H. Mitsuya, G. Franchini, M. Gutiérrez, M. Raffeld, E. Jaffe, G. Shearer, R. Yarchoan, W. Wilson (2003)
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.Blood, 101 12
(2012)
Impact of chemotherapy for AIDS-related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive ART
Aviva Joseph, J. Zheng, A. Follenzi, T. DiLorenzo, Kaori Sango, J. Hyman, Ken Chen, A. Piechocka-Trocha, C. Brander, E. Hooijberg, D. Vignali, B. Walker, H. Goldstein (2008)
Lentiviral Vectors Encoding Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Receptor Genes Efficiently Convert Peripheral Blood CD8 T Lymphocytes into Cytotoxic T Lymphocytes with Potent In Vitro and In Vivo HIV-1-Specific Inhibitory ActivityJournal of Virology, 82
S. Reuse, M. Calao, K. Kabeya, Allan Guiguen, J. Gatot, V. Quivy, C. Vanhulle, Aurélia Lamine, D. Vaira, D. Demonté, V. Martinelli, E. Veithen, T. Cherrier, V. Avettand, S. Poutrel, J. Piette, Y. Launoit, M. Moutschen, A. Burny, C. Rouzioux, S. Wit, G. Herbein, O. Rohr, Y. Collette, O. Lambotte, N. Clumeck, C. Lint (2009)
Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent InfectionPLoS ONE, 4
S. Kitchen, M. Bennett, Z. Galic, Joanne Kim, Qing Xu, A. Young, Alexis Lieberman, Aviva Joseph, H. Goldstein, Hwee Ng, O. Yang, J. Zack (2009)
Engineering Antigen-Specific T Cells from Genetically Modified Human Hematopoietic Stem Cells in Immunodeficient MicePLoS ONE, 4
D. Porter, B. Levine, M. Kalos, A. Bagg, C. June (2011)
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.The New England journal of medicine, 365 8
I. Huzicka (1999)
Could bone marrow transplantation cure AIDS?: review.Medical hypotheses, 52 3
P. Ashorn, B. Moss, J. Weinstein, V. Chaudhary, D. FitzGerald, I. Pastan, E. Berger (1990)
Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors.Proceedings of the National Academy of Sciences of the United States of America, 87
Long-term control of HIV by CCR5
First clinical study of vorinostat in HIV to demonstrate proof of concept that this drug may induce HIV from resting memory CD4 cells in patients on fully suppressive HAART
F. Porichis, D. Kaufmann (2012)
Role of PD-1 in HIV Pathogenesis and as Target for TherapyCurrent HIV/AIDS Reports, 9
E. Ravot, J. Lisziewicz, F. Lori (2012)
New Uses for Old Drugs in HIV InfectionDrugs, 58
S. Johansson, D. Goldenberg, G. Griffiths, B. Wahren, J. Hinkula (2006)
Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibodyAIDS, 20
E. Berger, B. Moss, I. Pastan (1998)
Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART.Proceedings of the National Academy of Sciences of the United States of America, 95 20
K. Boztug, M. Schmidt, A. Schwarzer, P. Banerjee, I. Díez, R. Dewey, M. Böhm, A. Nowrouzi, C. Ball, H. Glimm, S. Naundorf, K. Kühlcke, R. Blasczyk, I. Kondratenko, L. Maródi, J. Orange, C. Kalle, C. Klein (2010)
Stem-cell gene therapy for the Wiskott-Aldrich syndrome.The New England journal of medicine, 363 20
J. Lisziewicz, E. Rosenberg, J. Lieberman, H. Jessen, L. Lopalco, R. Siliciano, B. Walker, F. Lori (1999)
Control of HIV despite the discontinuation of antiretroviral therapy.The New England journal of medicine, 340 21
M. Cavazzana‐Calvo, E. Payen, O. Nègre, Gary Wang, K. Hehir, F. Fusil, J. Down, M. Denaro, Troy Brady, K. Westerman, R. Cavallesco, Béatrix Gillet-Legrand, L. Caccavelli, R. Sgarra, L. Maouche-Chretien, F. Bernaudin, R. Girot, R. Dorazio, G. Mulder, A. Polack, A. Bank, J. Soulier, J. Larghero, N. Kabbara, B. Dalle, B. Gourmel, G. Socié, S. Chrétien, N. Cartier, P. Aubourg, A. Fischer, K. Cornetta, F. Galactéros, Y. Beuzard, E. Gluckman, F. Bushman, S. Hacein-Bey-Abina, P. Leboulch (2010)
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaNature, 467
A. Fischer, S. Hacein-Bey-Abina, M. Cavazzana‐Calvo (2010)
20 years of gene therapy for SCIDNature Immunology, 11
J. Bamber (2012)
Climate change: Shrinking glaciers under scrutinyNature, 482
Lafeuillade Alain, H. Gilles, C. Stephane, M. Serge, Rieu Alain, Poggi Cécile (2002)
The HYDILE Trial: Efficacy and Tolerance of a Quadruple Combination of Reverse Transcriptase Inhibitors Versus the Same Regimen Plus Hydroxyurea or Hydroxyurea and Interleukin-2 in HIV-Infected Patients Failing Protease Inhibitor-Based CombinationsHIV Clinical Trials, 3
REVIEW URRENT PINION Ronald Mitsuyasu Purpose of review Interest in finding a potential ‘cure’ for HIV has taken on greater interest and urgency since the report of an individual who underwent allogeneic stem cell transplant from a CCR5 delta 32 homozygote donor after high-dose chemotherapy for acute myeloid leukemia. The potential role of cancer chemotherapy and other cancer-directed treatment approaches is discussed in the context of their potential role in helping to eliminate HIV from the infected host. Recent findings Cancer chemotherapy and other cancer-targeted agents have been used successfully in treating a variety of malignancies in both HIV-infected and HIV-uninfected individuals. Lessons learned from these strategies may be of importance in helping to define more effective ways of controlling and eliminating HIV as well. Application of these anticancer strategies to patients with HIV are beginning to be explored and may help determine their potential usefulness in this disease as well. Summary Although cytotoxic chemotherapy is a crude and not particularly effective way of removing HIV latently infected cells and tissue reservoirs, several new approaches to targeting and controlling cancer proliferation may be of value in HIV cure research and may one day help to end this disease. Keywords
Current Opinion in HIV and Aids – Wolters Kluwer Health
Published: May 1, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.